Immunotherapy with Keytruda (Pembolizumab) in Turkey typically costs from AUD $4,602 to AUD $13,944 per treatment cycle. The final price depends on the required dosage, the specific cancer type, and the medical hub chosen, such as Istanbul or Antalya. Patients save around 58% by travelling to Turkey from Australia, where this treatment costs AUD $11,016 on average. These fees generally cover the medication, infusion services, and oncology consultations.
Bookimed Expert Insight: Australian patients find exceptional value in Istanbul at clinics like Anadolu Medical Center. This facility is affiliated with Johns Hopkins Hospital (USA) and follows international ESMO protocols. Choosing such institutions ensures access to specialists like Professor Yesim Yildirim, who is ESMO-certified and holds over 20 years of experience. This combination of American-standard care and Turkish pharmaceutical pricing offers a significant financial advantage without compromising clinical excellence.
| Turkey | Thailand | South Korea | |
| Immunotherapy with Keytruda (Pembolizumab) | from AUD $4,602 | from AUD $11,155 | from AUD $7,251 |
Dr. Bulent Karagoz is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in immunotherapy and targeted therapies for sarcoma, lymphoma, and lung cancer. Dr. Karagoz provides treatment at a facility affiliated with the prestigious Johns Hopkins Hospital.
Dr Mustafa Solak brings elite international expertise to immunotherapy cases, having refined his skills at the University of Texas MD Anderson Cancer Center in the USA.
Dr. Sinan Karaaslan is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in treating breast, colorectal, and urogenital system cancers. Dr. Karaaslan brings clinical expertise from major institutions, including Medical Park and Gülhane Military Medical Academy. He works at a hospital affiliated with the Johns Hopkins Hospital.
Professor Yesim Yildirim is an ESMO-certified medical oncologist who completed specialised immuno-oncology training at the Mount Vernon Cancer Centre in the UK.